| 紫杉醇纳米制剂的研究进展 |
| |
| 引用本文： | 安飞,刘德杰,冷佳蔚. 紫杉醇纳米制剂的研究进展[J]. 药学研究, 2018, 37(10): 604-608 |
| |
| 作者姓名： | 安飞 刘德杰 冷佳蔚 |
| |
| 作者单位： | 1.山东大学药学院，山东 济南 250012；2.瑞阳制药有限公司，山东 淄博 256100,2.瑞阳制药有限公司，山东 淄博 256100,3.山东省食品药品检验研究院，山东 济南 250101 |
| |
| 摘 要： | 紫杉醇是微管抑制剂，临床用于治疗乳腺癌、卵巢癌等癌症的一线药物，溶解度较低为其临床应用带来诸多难题。纳米载体在药物递送中具有独特的优势，包括提高药物溶解度、增加药物循环时间、靶向运输至肿瘤部位、降低全身毒性等。本文综述了近几年紫杉醇纳米制剂的研究进展，为紫杉醇的进一步研究提供思路。
|
| 关 键 词： | 紫杉醇；纳米制剂；靶向给药 |
Research progress on paclitaxel nanoformulation |
| |
| AN Fei,LIU Dejie and LENG Jiawei. Research progress on paclitaxel nanoformulation[J]. Journal of Pharmaceutical Research, 2018, 37(10): 604-608 |
| |
| Authors: | AN Fei LIU Dejie LENG Jiawei |
| |
| Affiliation: | 1.College of Pharmacy,Shandong University,Jinan 250012,China;2.Reyoung Pharmaceutical Co.,Ltd.,Zibo 256100,China,1.College of Pharmacy,Shandong University,Jinan 250012,China;2.Reyoung Pharmaceutical Co.,Ltd.,Zibo 256100,China and 1.College of Pharmacy,Shandong University,Jinan 250012,China;2.Reyoung Pharmaceutical Co.,Ltd.,Zibo 256100,China |
| |
| Abstract: | Paclitaxel is a microtubule-binding compound that is clinically used for the treatment of breast cancer, ovarian cancer, and so on.The low solubility of paclitaxel leads to many problems for the clinical application.Nanocarriers have unique advantages in drug delivery, including improving drug solubility, increasing drug circulation time, targeting delivery to tumor sites, reducing systemic toxicity, and so on.This review summarized the research progress of paclitaxel nanopreparations in recent year for further research of paclitaxel. |
| |
| Keywords: | Paclitaxel Nanoformulation Targeted drug delivery |
|
| 点击此处可从《药学研究》浏览原始摘要信息 |
|
点击此处可从《药学研究》下载免费的PDF全文 |
|
